Novel gene encoding a dna repair endonuclease and methods of use thereof
CA 2298980 A1 · Owner: Fox Chase Cancer Center · Inventors: Bellacosa, Alfonso
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An isolated nucleic acid molecule encoding a human endonuclease MED1, is , disclosed. Like other mismatch repair genes which are mutated in certain cancers, MED1, encoding nucleic acids, proteins and antibodies thereto may be used to advantage in genetic or cancer screening assays. MED1 which , recognizes and cleaves DNA, may also be used for the diagnostic detection of mutations and genetic variants.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 28, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 28, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 28, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.